HeyJaredDawn Attride
- Indexed articles, last 90 days
- 13
- Latest publication
- Oct 1, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 10, 2026
Latest articles
Shorter-Course RT Is Safe Option for High-Risk Breast Cancer (opens the original)
Read excerpt
Locoregional recurrence remained low over 10 years in patients with high-risk breast cancer who received shorter courses of radiotherapy after mastectomy in a phase 3 trial. Among postmastectomy patients requiring regional nodal irradiation, hypofractionated radiotherapy and conventional fractionated radiotherapy showed comparable cumulative incidence of locoregional recurrence at 5 years (9.6% vs 8.6%), the primary endpoint of the trial. There were no significant differences in survival outcome
Stroke Rates Rise Sharply Among Younger Adults (opens the original)
Read excerpt
While the stroke rate among older adults in the US declined over the past 30 years, the rate among individuals aged 20-54 years nearly doubled, largely due to an increase in ischemic strokes, a new study showed. Despite the increase in the stroke rate in this age group, there was a slight decrease in short-term mortality between 1993 and 2020, which investigators said suggests that more young adults are living with post-stroke disability. “While stroke has traditionally been considered a disease
Novel Screen Quickly IDs Mental Illness, SUD, Suicide Risk (opens the original)
Read excerpt
A new 13-question mental health assessment combines various screening instruments into a single tool to rapidly identify a range of psychiatric disorders in patients seeking emergency treatment. The 13-item Mental Wellness Tool (mwTool-13) detected common or severe mental disorders, substance use disorders (SUDs), and suicide risk among patients in a psychiatric emergency department (ED). Compared to a routine psychiatric ED assessment, the tool identified the various conditions with high sensit
Add-On Lumateperone Tied to Improved Sexual Function in MDD (opens the original)
Read excerpt
Adding lumateperone to antidepressant therapy was associated with improved sexual function compared to placebo in patients with major depressive disorder (MDD), a new analysis showed. After 6 weeks of treatment, both men and women reported improvements in sexual functioning, pleasure, and arousal, which appear to be mediated through improvement in depressive symptoms, the investigators noted. “Adjunctive lumateperone 42 mg improves depressive symptoms without worsening sexual function, suitable
FDA Psychiatry Digest: August 2026 (opens the original)
Read excerpt
This digest highlights FDA actions in August related to therapeutics and diagnostics for neuropsychiatric illness. For information on approvals in other specialties during 2026, see our FDA Drug Approvals page. The FDA raised no objection to a planned phase 1 program for PT00114, an investigational neuropeptide for GAD. Manufacturer Protagenic Therapeutics said in a statement that the company’s investigational new drug application builds on studies conducted outside the US that showed PT00114 wa
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.